Business Context and Reporting Period
This Form 8-K is a current report filed by Avista Healthcare Public Acquisition Corp. (not Organogenesis Holdings Inc.) on November 28, 2016. The registrant is a Cayman Islands corporation operating as a Special Purpose Acquisition Company (SPAC). The report details the partial exercise of an over-allotment option from its initial public offering (IPO) and the commencement of separate trading for its units.
Key Financial Metrics
- Capital Raised: The Company received $9.8 million in net proceeds from the sale of 1,000,000 additional units.
- Private Placement: Sold 400,000 private placement warrants for an aggregate price of $200,000.
- Deferred Commissions: The net proceeds figure includes $350,000 payable to underwriters as deferred underwriting commissions.
- Liquidity: All proceeds from the unit sale and private placement warrants were deposited into the Company's trust account with Continental Stock Transfer and Trust Company.
- Warrant Terms: Warrants allow the purchase of one-half of one Class A ordinary share at an exercise price of $11.50 per share.
Material Changes
The primary material change reported is the increase in outstanding securities and trust capital resulting from the partial exercise of the underwriters' over-allotment option. Specifically, the Company issued an additional 1,000,000 units (comprising 1,000,000 Class A ordinary shares and 1,000,000 warrants) at the public offering price of $10.00 per unit. Additionally, the Company announced that units may now be separated for independent trading of shares and warrants.
Outlook and Management Commentary
- Trading Status: Commencing November 29, 2016, holders may elect to trade Class A ordinary shares and warrants separately. Units not separated will trade under the symbol AHPAU, while separated shares and warrants will trade under AHPA and AHPAW, respectively.
- Warrant Exercisability: Private placement warrants become exercisable on the later of 30 days after the completion of the initial business combination or October 14, 2017. They expire five years after the business combination or upon liquidation.
- Risks/Contingencies: The filing does not disclose specific operational risks or contingencies beyond standard SPAC warrant terms and the requirement to complete a business combination.
Investor Verification Checklist
- Verify the total amount of cash currently held in the trust account following the deposit of the $9.8 million net proceeds and $200,000 private placement proceeds.
- Confirm the exact number of outstanding Class A ordinary shares and warrants post-over-allotment exercise.
- Review the terms of the deferred underwriting commission ($350,000) to understand future cash outflow obligations upon a business combination.
- Monitor the trading volume and price spread between the combined units (AHPAU) and the separated components (AHPA/AHPAW) following the November 29, 2016 separation date.